Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplaston Therapy Effect on QT/QTc in DIPG
NCT02864888Phase 3Not yet recruiting
- Sponsor
- Burzynski Research Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of antineoplaston A10, antineoplaston AS2-1 in diffuse intrinsic brainstem glioma (DIPG), sponsored by Burzynski Research Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
diffuse intrinsic brainstem glioma (DIPG)
Beyond the preview
Go deeper on NCT02864888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864888.